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Detomidine is an alpha-2-adrenergic agonist widely used in horses. To evaluate changes in
muscular energy metabolism caused by detomidine continuous rate infusion in standing
horses, six adult animals were submitted to 1 hour 20 mg/kg/hr IV constant rate infusion
detomidine. Heart rate, respiratory rate (RR), mean arterial blood pressure, systolic blood
pressure, diastolic blood pressure, capillary reﬁll time, rectal temperature, plasma glucose,
blood lactate, total plasma protein, packed cell volume (PCV), hemoglobin (Hb), partial
arterial pressure of oxygen, partial arterial pressure of carbon dioxide (PaCO2), arterial
oxygen saturation, bicarbonate (HCO3), sodium, potassium, ionized calcium (iCa), arterial
oxygen content (CaO2), muscle glycogen, and muscle lactate were recorded before the
infusion, after 20, 40, and 60 minutes, when it was discontinued. One last sample was
obtained 1 hour after infusion was ﬁnished. Four animals were submitted to 1 hour saline
infusion as a control group. Constant rate infusion detomidine resulted in signiﬁcant
decrease in HR, RR, PCV, Hb, iCa, CaO2, and muscle glycogen in comparison with both
baseline and control groups and signiﬁcant increase in PaCO2, blood lactate, and HCO3.
Detomidine 20 mg/kg/hr produces minimal clinically signiﬁcant changes in horses, and it
does interfere with energy metabolism through mobilization of muscle glycogen and in-
crease in blood lactate.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Detomidine is an alpha-2-adrenergic agonist widely
used for sedation, analgesia, and anesthesia in horses for
standing surgeries, preanesthetic medication, and contin-
uous infusion during intraoperative and postoperativePPGMAE, UFRGS, Av
rpa).
. All rights reserved.periods [1,2]. Detomidine is characterized by having greater
speciﬁcity for adrenoceptors than xylazine, which increases
its potency [3].
The activation of alpha-2 receptors causes several
physiological changes. Bradycardia, decreased cardiac
output, and increased peripheral vascular resistance [4] in
addition to decreased insulin secretion [5,6] could lead to
both decreased tissue oxygenation and decreased energy
supply to muscles. The impact and extension of these
changes has still not been fully elucidated. Although other
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in horses sedated with detomidine and buprenorphine [7],
and even muscle glycogen and lactate under general
anesthesia with detomidine as preanesthetic medication
[8], none have reported detomidine alone in conscious
horses.
The objective of this study was to investigate whether a
constant rate infusion (CRI) of detomidine can interfere in
the energy metabolism, with special focus on muscular
metabolism. Six healthy adult horses were submitted to
continuous rate infusion of detomidine to evaluate the ef-
fects on several parameters of energetic metabolism, such
as plasma glucose and lactate, levels of muscle glycogen
and lactate, and other physiological parameters.
2. Materials and Methods
2.1. Animals
Ten clinically healthy adult horses from the teaching
herd (two Thoroughbred, one Percheron, one Brazilian
Sport Horse, and six mixed bred), four males and six fe-
males, weighing (body weight  standard deviation) 570
77 kg were used in the present study. The age varied from
10 to 15 years. Horses were allowed free access to water
and food until the beginning of the procedures. Study
design and methodology were approved by the Institu-
tional Animal Care and Use Committee of Federal Univer-
sity of Rio Grande do Sul and adhered to the principles for
the human treatment of animals in veterinary clinical
investigations.
2.2. Study Design
Horses were randomly divided into groups control
(CON, n ¼ 4), to receive saline infusion, and CRI detomidine
(DET, n ¼ 6), to receive 20 mg/kg/hr IV detomidine. A 14-ga
catheter was placed in the left jugular vein on each horse
under local anesthesia for infusion. Right jugular vein was
used for blood withdraw. Blood pressure was measured
noninvasively with oscillometric technique (Vet 420A;
Goldway US Inc, Smithtown, NY, EUA), with a cuff width of
0.4 of tail base circumference. Values of blood pressure
were not corrected to heart-tail height. Reference values for
blood pressure for standing horses with cuff placed on the
tail base were used [9].
A bolus of 20 mg/kg IV detomidine (Dormium V; Agener
União Saúde Animal, Embu-Guaçu, São Paulo, Brazil) was
used as a primer infusion in group DET. After signs of
sedation, as partial ﬂexion of the carpal joints, lowering of
the head, lip, and eyelid ptosis was detected and contin-
uous IV infusion of detomidine at a constant rate of 20 mg/
kg/hr was initiated and was maintained for 60 minutes in
group DET. Group CON received an identical bolus volume
of IV saline and had saline infusion initiated 10 minutes
after bolus and also maintained for 60minutes. The volume
of saline was identical to the total volume in the DET group.
Heart rate (HR), respiratory rate (RR), mean arterial
blood pressure (MAP), systolic blood pressure (SAP), dia-
stolic blood pressure (DAP), capillary reﬁll time (CRT), and
rectal temperature (RT) were recorded immediately beforebolus injection (T0), 20 minutes after (T20), 40 minutes
after (T40), and 60 minutes after beginning of infusions
(T60). One hour after the end of infusion (T120), data were
last collected. Simultaneously, venous blood samples were
collected into 4-mL EDTA vacuum tubes for determination
of plasma glucose, total plasma protein (TPP), and packed
cell volume (PCV). At T0 and T60, arterial blood samples
were taken with a 1-mL syringe from transversal facial
artery for blood lactate, partial arterial pressure of oxygen
(PaO2), partial arterial pressure of carbon dioxide (PaCO2),
arterial oxygen saturation (SaO2), pH, hemoglobin (Hb),
bicarbonate (HCO3), sodium (Naþ), potassium (Kþ), and
ionized calcium (iCa) analyses with a portable blood gas
self-calibrated analyzer (i-Stat Handheld Blood Analyzer;
Abbott, Chicago, IL). The arterial oxygen content (CaO2) was
calculatedwith the formula CaO2¼ (Hb 0.0139 SaO2)þ
(0.0031 PaO2) at T0 and T60. Two areas of 1510 cm over
the skin on the right and left superﬁcial gluteal muscle
were surgically prepared for muscle biopsy performed at
T0 and T60. Muscle biopsies of approximately 50 mg, 10 cm
deep into the muscle, were surgically taken under local
anesthesia from the areas prepared. Samples were imme-
diately frozen in liquid nitrogen and stored at 80C until
analysis to determinate muscle glycogen and muscle
lactate. Both molecular forms of glycogen, proglycogen
(PG), and macroglycogen (MG) were measured after
chemical extraction with hydrochloric acid and spectro-
photometer determination in g of glycosyl units per kg dry
matter as described elsewhere [10]. The horses were
restrained in a stock during the 120 minutes of study. All
animals studied were submitted to nonsteroidal analgesic
anti-inﬂammatory and antimicrobial treatment after the
experiment.
2.3. Statistical Analysis
Data were analyzed using a commercially available
software package (SPSS Statistics 17.0, Chicago, IL). Data
with ﬁve moments of collection were subjected to analysis
of variance (two way) and Tukey test as a post hoc. Data
with two moments of collection were subjected to Student
t test. Signiﬁcance was set at P < .05.
3. Results
All studied animals in group DET showed clear signs of
sedation such as relaxation, lip, and eyelid ptosis and
lowering of the head throughout the infusion time. No
central nervous system excitation or recumbency was
observed. After completion of the infusion, all horses in
group DET recovered from sedation within 30 minutes,
being able to walk at the end of the experiment.
Heart rate showed signiﬁcant decreased at T20, T40, and
T60 compared with T0 and T120 in group DET. Analysis of
RR showed signiﬁcant decrease in all times after detomi-
dine administration. There were no signiﬁcant changes in
MAP, SAP, DAP, CRT, and RT, although animals have showed
slightly decrease in RT (Table 1).
Values of PaO2, pH, SaO2, Naþ, and Kþ did not change
with CRI detomidine. The analysis of HCO3 and PaCO2
indicated increase at T60 in DET group compared with
Table 1
Values of heart rate, respiratory rate, systolic arterial pressure, diastolic arterial pressure, mean arterial pressure, capillary reﬁll time, and rectal temperature
in horses submitted to detomidine constant rate infusion (DET) or saline infusion (CON) before the infusion (T0), after 20 minutes of infusion (T20), after
40 minutes (T40), after 60 minutes (T60), and 60 minutes after the end of infusion (T120).
Variable Effects of Detomidine or Saline P Value
T0 T20 T40 T60 T120
Heart rate (bpm) .016a
DET 45 (13)b 27 (5)cd 29 (5)cd 28 (7)cd 37 (6)bd
CON 38 (4) 41 (7) 38 (4) 40 (6) 34 (2)
Respiratory rate (breaths/min) <.001a
DET 18 (8)b 10 (5)c 10 (4)c 8 (3)c 8 (3)c
CON 17 (7) 19 (3) 26 (6) 22 (8) 28 (9)
Systolic arterial pressure (mm Hg) .112
DET 125 (18) 122 (15) 118 (9) 119 (24) 111 (21)
CON 129 (10) 124 (17) 126 (17) 131 (5) 127 (17)
Diastolic arterial pressure (mm Hg) .696
DET 74 (14) 73 (18) 67 (20) 70 (26) 68 (11)
CON 79 (31) 69 (14) 64 (5) 62 (9) 67 (15)
Mean arterial pressure (mm Hg) .420
DET 91 (16) 91 (10) 78 (16) 90 (23) 90 (21)
CON 94 (22) 92 (19) 89 (11) 93 (7) 92 (11)
Capillary reﬁll time (s) .397
DET 1.5 (0.5) 1.5 (0.5) 1.7 (0.5) 1.7 (0.8) 1.7 (0.8)
CON 1.3 (0.5) 1.8 (0.5) 1.8 (0.5) 1.3 (0.5) 1.3 (0.5)
Rectal temperature (C) .432
DET 37.4 (0.4) 37.4 (0.6) 37.2 (0.7) 37.1 (0.7) 37.1 (0.5)
CON 37.2 (0.4) 37.5 (0.2) 37.5 (0.3) 37.4 (0.2) 37.3 (0.5)
Values are expressed asmeans (standard deviation). P values of treatment effect of two-way analysis of variance are provided. Superscript letters (b, c, and d)
indicate pairwise comparisons based on post hoc Tukey multiple comparison tests (P < .05).
Data without a superscript letter or data in the same row with the same superscript letter are not different from each other.
a Statistically signiﬁcant.
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between T0 and T60 in group DET however within physi-
ological ranges. Hemoglobin and CaO2 also presented
decreased values from baseline in group DET (Table 2).Table 2
Values of partial arterial pressure of oxygen (PaO2), partial arterial pres-
sure of carbon dioxide (PaCO2), pH, oxygen arterial saturation (SaO2), bi-
carbonate (HCO3), sodium (Naþ), potassium (Kþ), ionized calcium (iCa),
hemoglobin (Hb), and arterial oxygen content (CaO2) in horses studied at
T0, corresponding to baseline, and T60, after 60 minutes of detomidine
constant rate infusion (DET) or saline infusion (CON).
Variable Group T0 T60
PaO2 (mm Hg) DET 114 (43) 92 (12)
CON 98 (5) 119 (33)
PaCO2 (mm Hg) DET 42 (4) 49 (5)*
CON 41 (4) 39 (2)
pH DET 7.47 (0.04) 7.46 (0.03)
CON 7.46 (0.04) 7.47 (0.04)
SaO2 (%) DET 98 (1) 97 (1)
CON 98 (1) 99 (1)
HCO3 (mmol/L) DET 30 (2) 35 (2)**
CON 30 (1) 30 (2)
Naþ (mmol/L) DET 137 (1) 139 (2)
CON 134 (1) 135 (1)
Kþ (mmol/L) DET 3.8 (0.4) 3.7 (0.3)
CON 4.2 (0.3) 4.3 (0.4)
iCa (mmol/L) DET 1.61 (0.04) 1.50 (0.05)**
CON 1.67 (0.03) 1.61 (0.07)
Hb (g/dL) DET 13 (2) 10 (1)*
CON 11 (1) 11 (1)
CaO2 (mL/dL) DET 17 (3) 13 (2)*
CON 15 (1) 16 (2)
Values are expressed as means  standard deviation.
*P < .05.
**P < .01.Higher than normal plasma glucose levels were detec-
ted in all samples but the baseline in group DET, although
therewere no statistical differences between times studied.
A treatment effect in plasma glucose was observed (P <
.001). Blood lactate was signiﬁcantly different in T20 in
comparison with T0. Packed cell volume was different
during the infusion. There was no difference in TPP across
time (Table 3).
Proglycogen and the total amount of glycogen decreased
in DET group. Macroglycogen and muscle lactate did not
change with detomidine CRI. The CON group had no dif-
ference in the muscle contents over time, as shown in
Table 4.4. Discussion
This is the ﬁrst report on energetic muscle metabolism
evaluation in horses during CRI detomidine alone. This
study clearly shows that there is an impact with the use of
alpha-2 agonists in horses. Although these changes are
mild, they could be a potential problem in animals with
muscle disease or other metabolic dysfunctions.
Detomidine is an alpha-2-adrenoceptor agonist 50
times more potent than xylazine [11], and it has also more
speciﬁcity for those receptors [3]. After IV injection, deto-
midine is rapidly distributed and eliminated with a half-life
of approximately 30 minutes [12]. Because of its charac-
teristics, a continuous rate infusion of detomidine would be
necessary to produce constant plasma levels of the drug.
On the basis of elimination half-life, last data collectionwas
done 60 minutes after the end of infusion (T120) was
established.
Table 3
Values of glucose, lactate, total plasma protein, and packed cell volume in horses submitted to detomidine constant rate infusion (DET) or saline infusion
(CON) before the infusion (T0), after 20 minutes of infusion (T20), after 40 minutes (T40), after 60 minutes (T60), and 60 minutes after the end of infusion
(T120).
Variable Effects of Detomidine P Value
T0 T20 T40 T60 T120
Glucose (mg/dL) <.001a
DET 98 (19) 119 (28) 148 (42) 144 (53) 158 (57)
CON 96 (4) 96 (11) 97 (11) 101 (12) 92 (9)
Lactate (mmol/dL)b .202
DET 0.5 (0.2)c 1.3 (0.8)d 0.9 (0.2)c,d 0.9 (0.4)c,d 0.7 (0.3)c,d
CON 0.5 (0.1) 0.9 (0.2) 0.8 (0.1) 0.7 (0.2) 0.6 (0.3)
Total plasma protein (g/dL) .603
DET 7 (0.4) 6.9 (0.5) 6.8 (0.5) 6.7 (0.4) 6.7 (0.5)
CON 7.6 (0.6) 7.5 (0.6) 7.5 (0.4) 7.6 (0.4) 7.5 (0.4)
Packed cell volume (%)b <.001a
DET 38 (4)c 30 (6)d,e 31 (3)c,e 29 (5)d,e 26 (4)d,e
CON 32 (3) 31 (3) 30 (5) 33 (4) 30 (5)
Values are expressed as means  standard deviation. P values of treatment effect of two-way analysis of variance are provided. Superscript letters (c, d, and
e) indicate pairwise comparisons based on post hoc Tukey multiple comparison tests (P < .05).
Data without a superscript letter or data in the same row with the same superscript letter are not different from each other.
a Statistically signiﬁcant.
b Time effect P < .05. Lactate and PCV were signiﬁcantly different over time regardless of treatment.
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tion of neurotransmission by activation of potassium
channels at postsynaptic level [13] and inhibition of cal-
cium channels at presynaptic level [14]. It is mediated by
protein G-coupled receptors which inhibit adenylate
cyclase decreasing intracellular cyclic adenosine mono-
phosphate [15]. Through this mechanism, most detomidine
adverse effects, such as bradycardia and bradypnea that
occurred in this study, can be explained. Decrease in HR
with the use of alpha-2-adrenergic agonists is dose
dependent, as observed by Wagner et al [16]. This effect
occurs because of different mechanisms, such as the inhi-
bition of central norepinephrine release, as well as its
release by vesicles in synaptic terminal, increasing the
vagal tone triggered by baroreceptors in response to
increased peripheral vascular resistance and direct nega-
tive chronotropic effect at myocardium [17–20]. Bradypnea
was statistically signiﬁcant at all times because of alpha-2-
adrenergic agonist effects in locus coeruleus, inhibiting the
respiratory drive. Changing in breathing pattern charac-
terized by increased respiratory amplitude and greaterTable 4
Values of proglycogen (PG), macroglycogen (MG), total muscle glycogen,
and muscle lactate measured in muscle biopsies in studied horses at T0,
corresponding to baseline, and T60, after 60 minutes of detomidine con-
stant rate infusion (DET) or saline infusion (CON).
Variable Group T0 T60 P Value
PG (g/kg DW) DET 105  6 92  11 .028a
CON 102  13 96  2 .397
MG (g/kg DW) DET 91  4 87  6 .206
CON 87  9 82  6 .281
Total glycogen (g/kg DW) DET 196  4 179  13 .013a
CON 189  18 177  4 .272
Muscle lactate (g/kg DW) DET 29  3 29  1 .870
CON 25  3 25  1 .567
Abbreviation: DW, dry weight.
Values are expressed as means  standard deviation. P values of Student t
test are provided.
a Statistically signiﬁcant.pause between two respiratory cycles was observed in all
studied animals under detomidine effect. This observation
has been also described by Short et al [20] and is probably
because of muscle relaxation and its inﬂuence in the active
expiration phase in the horse.
IV administration of alpha-2 agonists are known to
produce an initial dose-dependant transient hypertension
followed by a moderated prolonged hypotension [18].
Normal arterial blood pressures were measured through
detomidine infusion. Detomidine CRI maintains plasma
levels of the drug and therefore its peripheral postsynaptic
alpha-2-receptor occupancy, which is responsible for the
maintenance of blood pressure values relatively normal
[3,18]. Even after the end of infusion, the arterial blood
pressure remained within normal physiological range in
our study.
Rectal temperature in our study was moderately below
the values considered normal for horses, although no sta-
tistical signiﬁcance was present in this variable. Virtanen
[21] describes the occurrence of hypothermia by central
inhibitory mechanisms of thermoregulation with alpha-2-
adrenoceptor agonists. The same author mentions hyper-
thermia with high doses of detomidine, which can be
induced by stimulation of alpha 1 receptors.
The administration of alpha-2-adrenergic agonists im-
pacts renal physiology [22] and can affect ion levels in
blood. Alpha-2 agonists are able to inhibit antidiuretic
hormone and renin release, with both mechanisms leading
to increased urine production [11,16,22,23]. Sodium and
potassium did not change signiﬁcantly, but iCa did,
although it was within normal reference range. Sodium,
potassium, and calcium ions are essential for maintenance
of blood volume, blood pressure, osmolar balance, muscle
contraction, and excitability of cell membranes. Because of
the importance of its regulation, the control of the con-
centration of these ions occurs through numerous different
mechanisms. Probably, only the increased activity of alpha-
2 adrenoceptors would not be sufﬁcient to cause important
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iCa values in some animals in T0 might have inﬂuenced the
results and may not be related to the drug effect.
The signiﬁcant decrease in PCV over time corroborates
the clinical evidence that alpha-2 agonists tend to cause
relaxation of the splenic capsule, producing splenomegaly
and erythrocytes sequestration. This ﬁnding is in agree-
ment with other authors [4,16]. In horses, there are no
studies describing the alpha receptors in the vascular bed of
the spleen, although Hanson et al [24] used xylazine and
epinephrine in horses to cause respectively decrease and
increase in PCV and to determine the spleen weight in
relation to changes in blood volume.
Alpha-2-adrenoceptor agonists decrease insulin
release–causing hyperglycemia [5,6]. In this study, we
could observe increased plasma glucose levels with the
highest being 248 mg/dL. Short et al [20] studied three
doses of detomidine (20, 80, and 160 mg/kg), and hyper-
glycemia was observed in all of them, although with
160 mg/kg blood glucose was not doubled compared with
80 mg/kg dose, indicating a maximum level of stimulus
produced by detomidine in horses.
The inhibition of insulin release by alpha-2 agonists can
also produce an impairment of blood glucose uptake in
insulin-dependent tissues, as muscle and adipose tissue. In
the absence of prompt blood glucose availability, muscle
tissue depends on its own glycogen reserves. According to
Bröjer [28], equine muscle glycogen is composed of two
pools of distinct molecules of glycogen: PG and MG. Pro-
glycogen is a low-molecular-weight molecule with high
protein binding. It composes a dynamic and easily mobi-
lized pool of glucose during exercise. This mobilizationwas
also observed during the standing sedation in this study,
with a decreased amount of PG in group DET. On the other
side, MG, a high-weight moleculewith low protein binding,
constitutes a steady energy reservoir and did not change
over time during CRI detomidine. The CON group had no
difference in the muscle contents during time, showing
that the standing position and instrumentation did not
affect muscle variables per se. In addition, animals with
previous metabolic or pathologic conditions could be
affected by administration of a drug with such effects. The
commonly observed difﬁculties during anesthesia recovery
after alpha-2-adrenoceptor agonists use may be caused by
a more extensive reduction in muscle glycogen content,
which was not evaluated in this study.
Muscle lactate content remained constant in both DET
and CON groups along time, showing that a possible over-
production of muscle lactate could have leaked into the
extracellular compartment to maintain the necessary bal-
ance of intracellular pH, resulting in the hyperlactatemia
presented. Once in the blood stream, lactate is removed by
erythrocytes, the largest consumers of lactate in the or-
ganism [24], which was indicated in this study by the re-
turn to normal values of lactate in T120. Therefore, our
hypothesis is that the hyperlactatemia observed during
alpha-2 agonists administration is not due to tissue hypoxia
resulted from decreased oxygen delivery (DO2) but by
increased muscle production because of its impossibility to
uptake blood glucose. This statement agrees with the new
concept of lactate playing an important role on energeticmetabolism maintenance during aerobic cellular activity
[25,26], for example its essential function of recycling
nicotinamide adenine dinucleotide for glycolysis. Lactate
can no more be considered only a waste product of anaer-
obic metabolism during anoxia or hypoxia. It is important
to highlight that the reduced PCV could also contributed to
the hyperlactatemia observed, with less red blood cells to
do the clearance of blood lactate.
The analysis of blood gases showed no statistical dif-
ference in PaO2, similar to what had been described by
Daunt and Steffey [4]. We also evidenced an increase in
PaCO2, followed by HCO3, which is probably because of the
decreased observed RR. Although a reduction in PCV was
observed, leading to a decreased CaO2, both DO2 and O2
extraction ratio were not evaluated, and no inference in O2
extraction ratio can be made. The alterations in DO2 by
alpha-2 agonists are not fully elucidated. Recently, Ringer
et al [27] evaluated the DO2 during CRI xylazine and
romiﬁdine in standing horses and found no difference in
DO2.
5. Conclusions
The use of 20 mg/kg/hr IV CRI detomidine during
60 minutes in standing horses does impact energy meta-
bolism through mobilization of muscle glycogen, hyper-
glycemia, and hypoinsulinemia. Muscle glycogen storage
was sufﬁcient to maintain muscle cells activity during the
period with less blood glucose availability. On the other
hand, this glycogen consumption can be deleterious in
horses with muscular metabolic disorders or in which re-
covery can be difﬁcult, deserving further investigation in
animals with this kind of compromise. Besides, detomidine
proved to be a good model of adrenergic stimuli to study
metabolic responses in horses.Acknowledgments
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